DIVESTITURES (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Proceeds from Divestiture of Businesses, Net of Cash Divested	$ 180	$ 195
Divestiture losses/(gains)	0	(16)
Royalty Income, Nonoperating	(135)	(158)
Diabetes business [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Proceeds from Divestiture of Businesses, Net of Cash Divested	164	153
Divestiture losses/(gains)	0	0
Royalty Income, Nonoperating	(134)	(127)
Erbitux [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Proceeds from Divestiture of Businesses, Net of Cash Divested	0	4
Divestiture losses/(gains)	0	0
Royalty Income, Nonoperating	0	0
Manufacturing Facility [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Proceeds from Divestiture of Businesses, Net of Cash Divested	0	0
Divestiture losses/(gains)	0	(1)
Royalty Income, Nonoperating	0	0
Avapro, Avalide, and Plavix [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Proceeds from Divestiture of Businesses, Net of Cash Divested	5	7
Divestiture losses/(gains)	0	(12)
Royalty Income, Nonoperating	0	0
Other divestitures [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Proceeds from Divestiture of Businesses, Net of Cash Divested	11	31
Divestiture losses/(gains)	0	(3)
Royalty Income, Nonoperating	$ (1)	$ (31)